Salute e Benessere

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European…

“Combined, the findings that will be showcased represent key steps along the developmental pathway of Cube's “go-to-market” strategy for its open-source AI platform as a service provider to many potential private sector partners and (academic) hospitals, as well as commercializing proprietary diagnostic products. This is only the beginning of our journey towards cutting-edge medical achievements,” said Dr. Dennis Makarawung, MD, PhD, the Company's Medical Director.One presentation...
Nasdaq GlobeNewswire
13/09/2024

Endo Presents Data at the American Orthopaedic Foot & Ankle Society Annual…

The oral presentation covered data from the Phase 2 clinical study of CCH in patients with plantar fibromatosis. The oral presentation covered data from the Phase 2 clinical study of CCH in patients with plantar fibromatosis. The results of the Phase 2 plantar fibromatosis study demonstrated a trend in CCH treatment effect over placebo for reducing pain associated with the condition as measured by the Foot Function Index Total Pain subscale score, as well as nominally significant...
PR Newswire
13/09/2024

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards®…

DUBLIN, Sept. 13, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 20, 2024. Now in its seventh year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. The program will offer grants to early-career investigators who have…
PR Newswire
13/09/2024

Opening Ceremony of BMC France Office

Over the past 23 years, BMC has continually strived to improve and innovate. The company has launched representative products such as PAP devices, CPAP masks, and sleep diagnostic devices. With service centers and a data management platform, BMC has achieved significant success in China, and its products are now sold in over 100 countries and regions. Over the past 23 years, BMC has continually strived to improve and innovate. The company has launched representative products such as PAP...
PR Newswire
13/09/2024

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

First mpox vaccine to obtain prequalification by the WHOApproval will help accelerate access to the vaccine for all African countries COPENHAGEN, Denmark, September 13, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that the Company has obtained prequalification from the World Health Organization (WHO) for IMVANEX ®(MVA-BN ® ) as the first mpox vaccine to be added to the WHO prequalification list. MVA-BN is indicated for active immunization against smallpox, mpox, and...
Nasdaq GlobeNewswire
13/09/2024

Jeanne Penn joins Cambridge Healthcare Research as Vice President, US Commercial…

Jeanne has been providing market insights to the biopharma industry for decades. Based in Boston, she has worked for Genzyme (now Sanofi) and EMD Serono (known as Merck KGaA outside the US) leading CI, market research, and forecasting for multiple brands. Her therapy area expertise is wide, but rare disease is where her heart will always be. Jeanne has been providing market insights to the biopharma industry for decades. Based inBoston, she has worked for Genzyme (now Sanofi) and EMD Serono...
PR Newswire
13/09/2024

ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight

As the ESMO 2024 annual meeting approaches, numerous pharmaceutical companies are preparing to present their latest data. DelveInsight invites you to discover the newest developments in oncology research and development. As the ESMO 2024 annual meeting approaches, numerous pharmaceutical companies are preparing to present their latest data. DelveInsight invites you to discover the newest developments in oncology research and development. The DelveInsight team is ready to provide exceptional...
PR Newswire
13/09/2024

Notification of managers' transactions

ANNOUNCEMENT NO. 274 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CFO Kim Nicolajsen in the attached PDF document.For further information, please contact:Kim Nicolajsen, CFO...
Nasdaq GlobeNewswire
13/09/2024

Kine Sciences Announces First Patient Dosed in the Phase 1b/2a Study in Patients…

KINE-101 is a novel nanopeptide and a disease modifier that controls both humoral immunity and cell-mediated immune responses by activating Treg cells. KINE-101 received FDA clearance for the Phase I study on September, 2021. The study was conducted in 40 healthy individuals in five cohorts assessed over 42 days. The design included four cohorts receiving intravenously administered ascending doses of KINE-101 (10, 30, 100, and 300 mg), and a cohort that received 96.8 mg of KINE-101…
PR Newswire
13/09/2024

Valneva Announces the Success of its Private Placement Raising approximately €60…

Saint-Herblain (France), September 13, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000. Peter Bühler, Valneva's Chief Financial Officer, commented, “We would like to thank our existing shareholders for their continued support, as well as the new healthcare specialist investors joining us through this...
Nasdaq GlobeNewswire
13/09/2024

FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous…

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous(IV) Tecentriq 1,2 New subcutaneous (SC) option reduces treatment time to approximately seven minutes, compared with 30-60 minutes for IV infusion 2 Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza TM...
Nasdaq GlobeNewswire
13/09/2024

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offering.Registration statements relating to the shares being sold in the offering have been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on September 12, 2024. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus...
Nasdaq GlobeNewswire
13/09/2024

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public…

BOSTON and LONDON, Sept.12, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering...
Nasdaq GlobeNewswire
13/09/2024

Valneva Announces the Launch of a Private Placement of Ordinary Shares for…

Saint-Herblain (France), September 12, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces its intention to issue, subject to market conditions, approximately 22.6 million new ordinary shares (the “ Offer Shares ”) at a price of €2.66 per Offer Share to certain categories of investors via a private placement through an accelerated bookbuilding process starting immediately. Context of the Offering The...
Nasdaq GlobeNewswire
12/09/2024

Stapokibart Was Granted Marketing Approval From National Medical Products…

The study showed that at week 52, the rates of achieving EASI-75 for the Stapokibart group and the placebo-to-Stapokibart group were 92.5% and 88.7%, respectively. The EASI-90 response rates were 77.1% and 65.6%, respectively. The rates of achieving an IGA score of 0 or 1 point with a reduction of ≥ 2 points from baseline were 67.3% and 64.2%, respectively. Long-term treatment with Stapokibart can consistently improve dermatitis symptoms and quality of life in subjects with moderate-to-severe…
PR Newswire
12/09/2024

SPINEWAY : Great success at the 24th AMCICO Congress in Mexico

Press release Ecully, September 12, 2024 – 6 p.m.SPINEWAYGreat success at the 24th AMCICO Congress in Mexico Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the24thAMCICO (Asociación Mexicana de Cirujanos de Columna)congress inCancúnfrom September 4 to 8, 2024.This annual congress of spine surgeons is a flagship event for the spine surgery sector in Mexico, the largest market in Central and...
Nasdaq GlobeNewswire
12/09/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of August 31, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (September 12, 2024 - 6:00 pm)– As of August 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses,...
Nasdaq GlobeNewswire
12/09/2024

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 10,110 divided into 10,110 new shares with a nominal value of DKK 1...
Nasdaq GlobeNewswire
12/09/2024

Vascular Stents Market to Grow from USD 11.4B in 2024 to USD 15.6B by 2029 |…

Browse in-depth TOC on "Vascular Stents Market" Browse in-depth TOC on "Vascular Stents Market" 620 - Tables 53 - Figures 426 - Pages Technological Advancements The vascular stent market is segmented by technology into covered stents, drug-eluting stents, bare metal stents, and bioabsorbable stents. As of 2023, drug-eluting stents hold the largest market share due to their clinical benefits, including a lower incidence of restenosis. These stents are coated with...
PR Newswire
12/09/2024

HeyGears to Launch New UltraCraft Reflex Series 3D Printer: Designed for…

HeyGears is inviting industry professionals and the 3D printing community to join the product launch event, which will be streamed on YouTube and Facebook on September 19, 2024, at 6:00 PM PDT. The event will offer a first look at the latest UltraCraft Reflex Series 3D printer, software updates, as well as newly developed resins, and provide insights into HeyGears' next steps in 3D printing. HeyGears is inviting industry professionals and the 3D printing community to join the product launch...
PR Newswire
12/09/2024

Surgical Microscopes Market Size to Grow USD 1,399.09 Million by 2030 at a CAGR…

Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-0N72/Surgical_Microscopes_Market Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-0N72/Surgical_Microscopes_Market Major Factors Driving Surgical Microscopes Market The global market for surgical microscopes is witnessing significant growth, driven by increasing demand across various medical fields such as neurosurgery, ophthalmology, ENT, and orthopedics. These microscopes enhance...
PR Newswire
12/09/2024

Landscaping Services Market to Reach $401.4 Billion, Globally, by 2034 at 3.8%…

Request The Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/A06341 Request The Sample PDF Of This Report:https://www.alliedmarketresearch.com/request-sample/A06341 Prime determinants of growth The rise in trend of sustainable and eco-friendly practices, such as xeriscaping and the use of native plants, has driven demand for landscaping services as clients seek environmentally responsible options in recent times. Technological innovations,...
PR Newswire
12/09/2024

B.More Collaborator, Dr. Michael Bogenschutz, Awarded NIAAA Grant for Psilocybin…

According to Carey Turnbull, Co-founder, and CEO of B.More Inc., "The awarding of this NIAAA grant is a significant recognition of Dr. Bogenschutz's pioneering work in developing new treatment modalities for alcohol use disorder. Building on the groundbreaking results of his well-publicized Phase 2a study on psilocybin for AUD, this trial has the potential to pave the way for more effective treatments for AUD and other substance use disorders, providing new hope for millions struggling with…
PR Newswire
12/09/2024

A Pioneering Achievement Strengthening the Kingdom's Leadership in Medicine

KFSHRC Performs the World's First Fully Robotic Heart Transplant RIYADH, Saudi Arabia, Sept.12, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) successfully performed the world's first fully robotic heart transplant on a 16-year-old patient suffering from end-stage heart failure. This pioneering achievement, overcoming the significant medical challenges associated with such procedures, reinforces KFSHRC's ability to innovate medical...
Nasdaq GlobeNewswire
12/09/2024
Altri  Comunicati